Patrick MacDonald Fisher
Overview
Explore the profile of Patrick MacDonald Fisher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jensen M, Stenbaek D, Sogaard Juul T, MacDonald Fisher P, Ekstrom C, Knudsen G, et al.
BMJ Open
. 2022 Oct;
12(10):e066019.
PMID: 36241352
Introduction: Alcohol use disorder is a difficult-to-treat psychiatric disorder and a major burden on public health. Existing treatment efficacy is moderate, and relapse rates are high. Preliminary findings suggest that...
12.
Klausen M, Jensen M, Moller M, Le Dous N, Jensen A, Zeeman V, et al.
JCI Insight
. 2022 Sep;
7(19).
PMID: 36066977
BackgroundAlcohol use disorder (AUD) is a chronic, relapsing brain disorder that accounts for 5% of deaths annually, and there is an urgent need to develop new targets for therapeutic intervention....
13.
Jensen K, McCulloch D, Olsen A, Bruzzone S, Larsen S, MacDonald Fisher P, et al.
Front Neurosci
. 2022 Jul;
16:855582.
PMID: 35774557
Hormonal contraceptive drugs are used by adolescent and adult women worldwide. Increasing evidence from human neuroimaging research indicates that oral contraceptives can alter regional functional brain connectivity and brain chemistry....
14.
McCulloch D, Knudsen G, Barrett F, Doss M, Carhart-Harris R, Rosas F, et al.
Neurosci Biobehav Rev
. 2022 May;
138:104689.
PMID: 35588933
Clinical research into serotonergic psychedelics is expanding rapidly, showing promising efficacy across myriad disorders. Resting-state functional magnetic resonance imaging (rs-fMRI) is a commonly used strategy to identify psychedelic-induced changes in...
15.
McCulloch D, Grzywacz M, Korsbak Madsen M, Jensen P, Ozenne B, Armand S, et al.
Front Pharmacol
. 2022 Mar;
13:841648.
PMID: 35355714
Psychedelic drugs such as psilocybin have shown substantial promise for the treatment of several psychiatric conditions including mood and addictive disorders. They also have the remarkable property of producing persisting...
16.
Raval N, Gudmundsen F, Juhl M, Andersen I, Speth N, Videbaek A, et al.
Front Synaptic Neurosci
. 2021 Dec;
13:715811.
PMID: 34867258
Parkinson's disease (PD) is caused by progressive neurodegeneration and characterised by motor dysfunction. Neurodegeneration of dopaminergic neurons also causes aberrations within the cortico-striato-thalamo-cortical (CSTC) circuit, which has been hypothesised to...
17.
Bjertrup A, Macoveanu J, Laurent H, Moszkowicz M, Finnegan M, Egmose I, et al.
Eur Neuropsychopharmacol
. 2021 Oct;
54:7-20.
PMID: 34706300
Motherhood involves functional brain adaptations within a broad neural network purported to underlie sensitive caregiving behavior. Bipolar disorder (BD) is associated with aberrant brain response to emotional faces within a...
18.
Macoveanu J, Kjaerstad H, Vinberg M, Harmer C, MacDonald Fisher P, Knudsen G, et al.
J Affect Disord
. 2021 Sep;
295:647-656.
PMID: 34509780
Introduction: Bipolar disorder (BD) is often accompanied by trait-related cognitive impairments, but it is unclear which neurocircuitry abnormalities give rise to these impairments and whether neurocircuitry differences are exacerbated with...
19.
McCulloch D, Korsbak Madsen M, Stenbaek D, Kristiansen S, Ozenne B, Jensen P, et al.
J Psychopharmacol
. 2021 Jun;
36(1):74-84.
PMID: 34189985
Background: Psilocybin is a psychedelic drug that has shown lasting positive effects on clinical symptoms and self-reported well-being following a single dose. There has been little research into the long-term...
20.
Stenbaek D, Korsbak Madsen M, Ozenne B, Kristiansen S, Burmester D, Erritzoe D, et al.
J Psychopharmacol
. 2021 Jan;
35(4):459-468.
PMID: 33501857
Background: Psilocybin is a serotonergic psychedelic with psychoactive effects mediated by serotonin 2A receptor (5-HT2AR) activation. It produces an acute psychedelic altered state of consciousness with a unique phenomenology that...